456 related articles for article (PubMed ID: 22830335)
41. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions.
Gopal YN; Chanchorn E; Van Dyke MW
Mol Cancer Ther; 2009 Mar; 8(3):552-62. PubMed ID: 19276167
[TBL] [Abstract][Full Text] [Related]
42. Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action.
Voruganti S; Qin JJ; Sarkar S; Nag S; Walbi IA; Wang S; Zhao Y; Wang W; Zhang R
Oncotarget; 2015 Aug; 6(25):21379-94. PubMed ID: 26041888
[TBL] [Abstract][Full Text] [Related]
43. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
45. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Shangary S; Wang S
Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
[TBL] [Abstract][Full Text] [Related]
46. Targeting the p53-MDM2 interaction to treat cancer.
Klein C; Vassilev LT
Br J Cancer; 2004 Oct; 91(8):1415-9. PubMed ID: 15452548
[TBL] [Abstract][Full Text] [Related]
47. The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.
Clark RC; Lee SY; Searcey M; Boger DL
Nat Prod Rep; 2009 Apr; 26(4):465-77. PubMed ID: 19642417
[TBL] [Abstract][Full Text] [Related]
48. Resistance acquisition to MDM2 inhibitors.
Cinatl J; Speidel D; Hardcastle I; Michaelis M
Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
[TBL] [Abstract][Full Text] [Related]
49. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and biological evaluation of novel potent MDM2/p53 small-molecule inhibitors.
Ivanenkov YA; Vasilevski SV; Beloglazkina EK; Kukushkin ME; Machulkin AE; Veselov MS; Chufarova NV; Chernyaginab ES; Vanzcool AS; Zyk NV; Skvortsov DA; Khutornenko AA; Rusanov AL; Tonevitsky AG; Dontsova OA; Majouga AG
Bioorg Med Chem Lett; 2015 Jan; 25(2):404-9. PubMed ID: 25479770
[TBL] [Abstract][Full Text] [Related]
51. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
52. MDM2 inhibitors for pancreatic cancer therapy.
Azmi AS; Philip PA; Almhanna K; Beck FW; Sarkar FH; Mohammad RM
Mini Rev Med Chem; 2010 Jun; 10(6):518-26. PubMed ID: 20377522
[TBL] [Abstract][Full Text] [Related]
53. p53-Mdm2 inhibitors: patent review (2009 - 2010).
Kamal A; Mohammed AA; Shaik TB
Expert Opin Ther Pat; 2012 Feb; 22(2):95-105. PubMed ID: 22316395
[TBL] [Abstract][Full Text] [Related]
54. Proposing novel MDM2 inhibitors: Combined physics-driven high-throughput virtual screening and in vitro studies.
Aydin G; Paksoy MN; Orhan MD; Avsar T; Yurtsever M; Durdagi S
Chem Biol Drug Des; 2020 Jul; 96(1):684-700. PubMed ID: 32691963
[TBL] [Abstract][Full Text] [Related]
55. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
56. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
[TBL] [Abstract][Full Text] [Related]
57. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
58. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA
Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429
[TBL] [Abstract][Full Text] [Related]
59. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
[TBL] [Abstract][Full Text] [Related]
60. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
